Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$2.74 - $4.79 $131,520 - $229,920
-48,000 Reduced 19.35%
200,000 $618,000
Q2 2023

Aug 14, 2023

BUY
$4.45 - $8.12 $1.1 Million - $2.01 Million
248,000 New
248,000 $1.12 Million
Q4 2020

Feb 16, 2021

SELL
$28.81 - $88.94 $5.17 Million - $16 Million
-179,361 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$26.2 - $30.13 $4.7 Million - $5.4 Million
179,361 New
179,361 $5.4 Million

Others Institutions Holding PRLD

About Prelude Therapeutics Inc


  • Ticker PRLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,369,200
  • Market Cap $75.3M
  • Description
  • Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...
More about PRLD
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.